TheraTech re-acquires some rights to patch:
This article was originally published in Clinica
TheraTech, a developer of drug delivery products based in Salt Lake City, Utah, plans to re-acquire the marketing rights to its male testosterone patch from SmithKline Beecham in certain countries. SmithKline will continue to market the product in North America, the UK and Ireland.
You may also be interested in...
Siemens Healthineers' product mix of diagnostics and imaging products meant it was in the middle of a very dynamic situation when COVID-19 struck.
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.